FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1779-1790 April 28, 2005 Number 17 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Perspective by Goldman, J. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are clonal myeloproliferative disorders arising from a multipotent progenitor. The loss of heterozygosity (LOH) on the short arm of chromosome 9 (9pLOH) in myeloproliferative disorders suggests that 9p harbors a mutation that contributes to the cause of clonal expansion of hematopoietic cells in these diseases.

Methods We performed microsatellite mapping of the 9pLOH region and DNA sequencing in 244 patients with myeloproliferative disorders (128 with polycythemia vera, 93 with essential thrombocythemia, and 23 with idiopathic myelofibrosis).

Results Microsatellite mapping identified a 9pLOH region that included the Janus kinase 2 (JAK2) gene. In patients with 9pLOH, JAK2 had a homozygous GT transversion, causing phenylalanine to be substituted for valine at position 617 of JAK2 (V617F). All 51 patients with 9pLOH had the V617F mutation. Of 193 patients without 9pLOH, 66 were heterozygous for V617F and 127 did not have the mutation. The frequency of V617F was 65 percent among patients with polycythemia vera (83 of 128), 57 percent among patients with idiopathic myelofibrosis (13 of 23), and 23 percent among patients with essential thrombocythemia (21 of 93). V617F is a somatic mutation present in hematopoietic cells. Mitotic recombination probably causes both 9pLOH and the transition from heterozygosity to homozygosity for V617F. Genetic evidence and in vitro functional studies indicate that V617F gives hematopoietic precursors proliferative and survival advantages. Patients with the V617F mutation had a significantly longer duration of disease and a higher rate of complications (fibrosis, hemorrhage, and thrombosis) and treatment with cytoreductive therapy than patients with wild-type JAK2.

Conclusions A high proportion of patients with myeloproliferative disorders carry a dominant gain-of-function mutation of JAK2.

Source Information

From the Department of Research, Experimental Hematology (R.K., S.-S.T., R.T., R.C.S.), and the Departments of Hematology (A.S.B., J.R.P.) and Laboratory Medicine (A.T.), University Hospital Basel, Basel, Switzerland; and the Division of Hematology, University of Pavia Medical School and Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy (F.P., M.C.).

Address reprint requests to Dr. Skoda at the Department of Research, University Hospital Basel, Hebelstr. 20, CH-4031 Basel, Switzerland, or at radek.skoda{at}unibas.ch.

Full Text of this Article

Related Letters:

JAK2 Mutations in Myeloproliferative Disorders
Tefferi A., Lasho T. L., Gilliland G., Kralovics R., Cazzola M., Skoda R. C.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:1416-1417, Sep 29, 2005. Correspondence

This article has been cited by other articles:

• McDermott, U., Settleman, J. (2009). Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology. JCO 27: 5650-5659 [Abstract] [Full Text]  
• Liu, P. C.C., Caulder, E., Li, J., Waeltz, P., Margulis, A., Wynn, R., Becker-Pasha, M., Li, Y., Crowgey, E., Hollis, G., Haley, P., Sparks, R. B., Combs, A. P., Rodgers, J. D., Burn, T. C., Vaddi, K., Fridman, J. S. (2009). Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity. Clin. Cancer Res. 15: 6891-6900 [Abstract] [Full Text]  
• Quintas-Cardama, A., Kantarjian, H., Manshouri, T., Luthra, R., Estrov, Z., Pierce, S., Richie, M. A., Borthakur, G., Konopleva, M., Cortes, J., Verstovsek, S. (2009). Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera. JCO 27: 5418-5424 [Abstract] [Full Text]  
• Cankovic, M., Whiteley, L., Hawley, R. C., Zarbo, R. J., Chitale, D. (2009). Clinical Performance of JAK2 V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory: Evaluation of Screening and Quantitation Methods. Am J Clin Pathol 132: 713-721 [Abstract] [Full Text]  
• Pieri, L., Bogani, C., Guglielmelli, P., Zingariello, M., Rana, R. A., Bartalucci, N., Bosi, A., Vannucchi, A. M. (2009). The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. haematol 94: 1537-1545 [Abstract] [Full Text]  
• Quintas-Cardama, A., Kantarjian, H. M., Manshouri, T., Thomas, D., Cortes, J., Ravandi, F., Garcia-Manero, G., Ferrajoli, A., Bueso-Ramos, C., Verstovsek, S. (2009). Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis. JCO 27: 4760-4766 [Abstract] [Full Text]  
• Lambert, J. R., Everington, T., Linch, D. C., Gale, R. E. (2009). In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood 114: 3018-3023 [Abstract] [Full Text]  
• Navarro, A., Diaz, T., Martinez, A., Gaya, A., Pons, A., Gel, B., Codony, C., Ferrer, G., Martinez, C., Montserrat, E., Monzo, M. (2009). Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 114: 2945-2951 [Abstract] [Full Text]  
• Haeno, H., Levine, R. L., Gilliland, D. G., Michor, F. (2009). A progenitor cell origin of myeloid malignancies. Proc. Natl. Acad. Sci. USA 106: 16616-16621 [Abstract] [Full Text]  
• Zhao, L., Dong, H., Zhang, C. C., Kinch, L., Osawa, M., Iacovino, M., Grishin, N. V., Kyba, M., Huang, L. J.-s. (2009). A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase Activation. J. Biol. Chem. 284: 26988-26998 [Abstract] [Full Text]  
• Pich, A, Riera, L, Sismondi, F, Godio, L, Bonino, L D., Marmont, F, di Celle, P F. (2009). JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia. J. Clin. Pathol. 62: 798-801 [Abstract] [Full Text]  
• Wood, A. D., Chen, E., Donaldson, I. J., Hattangadi, S., Burke, K. A., Dawson, M. A., Miranda-Saavedra, D., Lodish, H. F., Green, A. R., Gottgens, B. (2009). ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling. Blood 114: 1820-1830 [Abstract] [Full Text]  
• Usenko, T., Li, Y.-J., Haeri, M., Li, Y., Vecchiarelli-Federico, L. M., Zhao, X., Prchal, J. T., Ben-David, Y. (2009). Enrichment of Sca1+ hematopoietic progenitors in polycythemic mice inhibits leukemogenesis. Blood 114: 1831-1841 [Abstract] [Full Text]  
• Jedidi, A., Marty, C., Oligo, C., Jeanson-Leh, L., Ribeil, J.-A., Casadevall, N., Galy, A., Vainchenker, W., Villeval, J.-L. (2009). Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood 114: 1842-1851 [Abstract] [Full Text]  
• Kaya, K., Cavolli, R., Telli, A., Tasoz, R. (2009). Off-pump coronary artery surgery in a patient with essential thrombocythaemia: two life-threatening complications in the same patient. BMJ Case Reports 2009: bcr0120091503-bcr0120091503 [Abstract] [Full Text]  
• Guglielmelli, P., Barosi, G., Specchia, G., Rambaldi, A., Lo Coco, F., Antonioli, E., Pieri, L., Pancrazzi, A., Ponziani, V., Delaini, F., Longo, G., Ammatuna, E., Liso, V., Bosi, A., Barbui, T., Vannucchi, A. M. (2009). Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 114: 1477-1483 [Abstract] [Full Text]  
• Saint-Martin, C., Leroy, G., Delhommeau, F., Panelatti, G., Dupont, S., James, C., Plo, I., Bordessoule, D., Chomienne, C., Delannoy, A., Devidas, A., Gardembas-Pain, M., Isnard, F., Plumelle, Y., Bernard, O., Vainchenker, W., Najman, A., Bellanne-Chantelot, C., the French Group of Familial Myeloproliferative Di, (2009). Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 114: 1628-1632 [Abstract] [Full Text]  
• Thiele, J. (2009). Philadelphia Chromosome-Negative Chronic Myeloproliferative Disease. Am J Clin Pathol 132: 261-280 [Abstract] [Full Text]  
• Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellstrom-Lindberg, E., Tefferi, A., Bloomfield, C. D. (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951 [Abstract] [Full Text]  
• Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., Huberman, K., Thomas, S., Dolgalev, I., Heguy, A., Paietta, E., Le Beau, M. M., Beran, M., Tallman, M. S., Ebert, B. L., Kantarjian, H. M., Stone, R. M., Gilliland, D. G., Crispino, J. D., Levine, R. L. (2009). Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114: 144-147 [Abstract] [Full Text]  
• Vannucchi, A. M., Masala, G., Antonioli, E., Chiara Susini, M., Guglielmelli, P., Pieri, L., Maggi, L., Caini, S., Palli, D., Bogani, C., Ponziani, V., Pancrazzi, A., Annunziato, F., Bosi, A. (2009). Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Cancer Epidemiol. Biomarkers Prev. 18: 2068-2073 [Abstract] [Full Text]  
• Shah, S. P., Kobel, M., Senz, J., Morin, R. D., Clarke, B. A., Wiegand, K. C., Leung, G., Zayed, A., Mehl, E., Kalloger, S. E., Sun, M., Giuliany, R., Yorida, E., Jones, S., Varhol, R., Swenerton, K. D., Miller, D., Clement, P. B., Crane, C., Madore, J., Provencher, D., Leung, P., DeFazio, A., Khattra, J., Turashvili, G., Zhao, Y., Zeng, T., Glover, J.N. M., Vanderhyden, B., Zhao, C., Parkinson, C. A., Jimenez-Linan, M., Bowtell, D. D.L., Mes-Masson, A.-M., Brenton, J. D., Aparicio, S. A., Boyd, N., Hirst, M., Gilks, C. B., Marra, M., Huntsman, D. G. (2009). Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary. NEJM 360: 2719-2729 [Abstract] [Full Text]  
• Campbell, P. J., Bareford, D., Erber, W. N., Wilkins, B. S., Wright, P., Buck, G., Wheatley, K., Harrison, C. N., Green, A. R. (2009). Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy. JCO 27: 2991-2999 [Abstract] [Full Text]  
• Jankowska, A. M., Szpurka, H., Tiu, R. V., Makishima, H., Afable, M., Huh, J., O'Keefe, C. L., Ganetzky, R., McDevitt, M. A., Maciejewski, J. P. (2009). Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 113: 6403-6410 [Abstract] [Full Text]  
• Grand, F. H., Hidalgo-Curtis, C. E., Ernst, T., Zoi, K., Zoi, C., McGuire, C., Kreil, S., Jones, A., Score, J., Metzgeroth, G., Oscier, D., Hall, A., Brandts, C., Serve, H., Reiter, A., Chase, A. J., Cross, N. C. P. (2009). Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113: 6182-6192 [Abstract] [Full Text]  
• Mullighan, C. G., Zhang, J., Harvey, R. C., Collins-Underwood, J. R., Schulman, B. A., Phillips, L. A., Tasian, S. K., Loh, M. L., Su, X., Liu, W., Devidas, M., Atlas, S. R., Chen, I-M., Clifford, R. J., Gerhard, D. S., Carroll, W. L., Reaman, G. H., Smith, M., Downing, J. R., Hunger, S. P., Willman, C. L. (2009). JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 106: 9414-9418 [Abstract] [Full Text]  
• Ishii, T., Wang, J., Zhang, W., Mascarenhas, J., Hoffman, R., Dai, Y., Wisch, N., Xu, M. (2009). Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood 113: 5942-5950 [Abstract] [Full Text]  
• Gery, S., Cao, Q., Gueller, S., Xing, H., Tefferi, A., Koeffler, H. P. (2009). Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F. J. Leukoc. Biol. 85: 957-965 [Abstract] [Full Text]  
• Dentali, F., Squizzato, A., Brivio, L., Appio, L., Campiotti, L., Crowther, M., Grandi, A. M., Ageno, W. (2009). JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113: 5617-5623 [Abstract] [Full Text]  
• Tyner, J. W., Deininger, M. W., Loriaux, M. M., Chang, B. H., Gotlib, J. R., Willis, S. G., Erickson, H., Kovacsovics, T., O'Hare, T., Heinrich, M. C., Druker, B. J. (2009). RNAi screen for rapid therapeutic target identification in leukemia patients. Proc. Natl. Acad. Sci. USA 106: 8695-8700 [Abstract] [Full Text]  
• Sozer, S., Fiel, M. I., Schiano, T., Xu, M., Mascarenhas, J., Hoffman, R. (2009). The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 113: 5246-5249 [Abstract] [Full Text]  
• Funakoshi-Tago, M., Tago, K., Sumi, K., Abe, M., Aizu-Yokota, E., Oshio, T., Sonoda, Y., Kasahara, T. (2009). The Acute Lymphoblastic Leukemia-associated JAK2 L611S Mutant Induces Tumorigenesis in Nude Mice. J. Biol. Chem. 284: 12680-12690 [Abstract] [Full Text]  
• Vannucchi, A. M., Guglielmelli, P., Tefferi, A. (2009). Advances in Understanding and Management of Myeloproliferative Neoplasms. CA Cancer J Clin 59: 171-191 [Abstract] [Full Text]  
• Florena, A M, Tripodo, C, Di Bernardo, A, Iannitto, E, Guarnotta, C, Porcasi, R, Ingrao, S, Abbadessa, V, Franco, V (2009). Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis. J. Clin. Pathol. 62: 331-338 [Abstract] [Full Text]  
• Elliott, J., Suessmuth, Y., Scott, L. M., Nahlik, K., McMullin, M. F., Constantinescu, S. N., Green, A. R., Johnston, J. A. (2009). SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. haematol 94: 576-580 [Abstract] [Full Text]  
• Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J.-L., Barosi, G., Rumi, E., Tefferi, A. (2009). New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113: 2895-2901 [Abstract] [Full Text]  
• Hornakova, T., Staerk, J., Royer, Y., Flex, E., Tartaglia, M., Constantinescu, S. N., Knoops, L., Renauld, J.-C. (2009). Acute Lymphoblastic Leukemia-associated JAK1 Mutants Activate the Janus Kinase/STAT Pathway via Interleukin-9 Receptor {alpha} Homodimers. J. Biol. Chem. 284: 6773-6781 [Abstract] [Full Text]  
• Rapado, I., Grande, S., Albizua, E., Ayala, R., Hernandez, J.-A., Gallardo, M., Gilsanz, F., Martinez-Lopez, J. (2009). High Resolution Melting Analysis for JAK2 Exon 14 and Exon 12 Mutations: A Diagnostic Tool for Myeloproliferative Neoplasms. J. Mol. Diagn. 11: 155-161 [Abstract] [Full Text]  
• Andrikovics, H., Meggyesi, N., Szilvasi, A., Tamaska, J., Halm, G., Lueff, S., Nahajevszky, S., Egyed, M., Varkonyi, J., Mikala, G., Sipos, A., Kalasz, L., Masszi, T., Tordai, A. (2009). HFE C282Y Mutation as a Genetic Modifier Influencing Disease Susceptibility for Chronic Myeloproliferative Disease. Cancer Epidemiol. Biomarkers Prev. 18: 929-934 [Abstract] [Full Text]  
• Schnittger, S., Bacher, U., Haferlach, C., Geer, T., Muller, P., Mittermuller, J., Petrides, P., Schlag, R., Sandner, R., Selbach, J., Slawik, H. R., Tessen, H. W., Wehmeyer, J., Kern, W., Haferlach, T. (2009). Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. haematol 94: 414-418 [Abstract] [Full Text]  
• Schaub, F. X., Jager, R., Looser, R., Hao-Shen, H., Hermouet, S., Girodon, F., Tichelli, A., Gisslinger, H., Kralovics, R., Skoda, R. C. (2009). Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood 113: 2022-2027 [Abstract] [Full Text]  
• Seaman, V., Jumaan, A., Yanni, E., Lewis, B., Neyer, J., Roda, P., Xu, M., Hoffman, R. (2009). Use of Molecular Testing to Identify a Cluster of Patients with Polycythemia Vera in Eastern Pennsylvania. Cancer Epidemiol. Biomarkers Prev. 18: 534-540 [Abstract] [Full Text]  
• Passamonti, F., Rumi, E. (2009). Clinical relevance of JAK2 (V617F) mutant allele burden. haematol 94: 7-10 [Full Text]  
• Ma, W., Kantarjian, H., Zhang, X., Yeh, C.-H., Zhang, Z. J., Verstovsek, S., Albitar, M. (2009). Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias. J. Mol. Diagn. 11: 49-53 [Abstract] [Full Text]  
• Lippert, E., Girodon, F., Hammond, E., Jelinek, J., Reading, N. S., Fehse, B., Hanlon, K., Hermans, M., Richard, C., Swierczek, S., Ugo, V., Carillo, S., Harrivel, V., Marzac, C., Pietra, D., Sobas, M., Mounier, M., Migeon, M., Ellard, S., Kroger, N., Herrmann, R., Prchal, J. T., Skoda, R. C., Hermouet, S. (2009). Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. haematol 94: 38-45 [Abstract] [Full Text]  
• Zhao, R., Follows, G. A., Beer, P. A., Scott, L. M., Huntly, B. J.P., Green, A. R., Alexander, D. R. (2008). Inhibition of the Bcl-xL Deamidation Pathway in Myeloproliferative Disorders. NEJM 359: 2778-2789 [Abstract] [Full Text]  
• Dunbar, A. J., Gondek, L. P., O'Keefe, C. L., Makishima, H., Rataul, M. S., Szpurka, H., Sekeres, M. A., Wang, X. F., McDevitt, M. A., Maciejewski, J. P. (2008). 250K Single Nucleotide Polymorphism Array Karyotyping Identifies Acquired Uniparental Disomy and Homozygous Mutations, Including Novel Missense Substitutions of c-Cbl, in Myeloid Malignancies. Cancer Res. 68: 10349-10357 [Abstract] [Full Text]  
• Theocharides, A., Passweg, J. R., Medinger, M., Looser, R., Li, S., Hao-Shen, H., Buser, A. S., Gratwohl, A., Tichelli, A., Skoda, R. C. (2008). The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. haematol 93: 1890-1893 [Abstract] [Full Text]  
• Malka, Y., Hornakova, T., Royer, Y., Knoops, L., Renauld, J.-C., Constantinescu, S. N., Henis, Y. I. (2008). Ligand-independent Homomeric and Heteromeric Complexes between Interleukin-2 or -9 Receptor Subunits and the {gamma} Chain. J. Biol. Chem. 283: 33569-33577 [Abstract] [Full Text]  
• Marchetti, M., Castoldi, E., Spronk, H. M. H., van Oerle, R., Balducci, D., Barbui, T., Rosing, J., ten Cate, H., Falanga, A. (2008). Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 112: 4061-4068 [Abstract] [Full Text]  
• Passamonti, F., Rumi, E., Arcaini, L., Boveri, E., Elena, C., Pietra, D., Boggi, S., Astori, C., Bernasconi, P., Varettoni, M., Brusamolino, E., Pascutto, C., Lazzarino, M. (2008). Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. haematol 93: 1645-1651 [Abstract] [Full Text]  
• Fourouclas, N., Li, J., Gilby, D. C., Campbell, P. J., Beer, P. A., Boyd, E. M., Goodeve, A. C., Bareford, D., Harrison, C. N., Reilly, J. T., Green, A. R., Bench, A. J. (2008). Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. haematol 93: 1635-1644 [Abstract] [Full Text]  
• Kiladjian, J.-J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, B., Chomienne, C., Fenaux, P. (2008). Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112: 3065-3072 [Abstract] [Full Text]  
• Lataillade, J.-J., Pierre-Louis, O., Hasselbalch, H. C., Uzan, G., Jasmin, C., Martyre, M.-C., Le Bousse-Kerdiles, M.-C., on behalf of the French INSERM and the European EU, (2008). Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 112: 3026-3035 [Abstract] [Full Text]  
• Jones, A. V., Cross, N. C.P., White, H. E., Green, A. R., Scott, L. M. (2008). Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. haematol 93: 1560-1564 [Abstract] [Full Text]  
• Levine, R. L., Gilliland, D. G. (2008). Myeloproliferative disorders. Blood 112: 2190-2198 [Abstract] [Full Text]  
• James, C., Mazurier, F., Dupont, S., Chaligne, R., Lamrissi-Garcia, I., Tulliez, M., Lippert, E., Mahon, F.-X., Pasquet, J.-M., Etienne, G., Delhommeau, F., Giraudier, S., Vainchenker, W., de Verneuil, H. (2008). The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood 112: 2429-2438 [Abstract] [Full Text]  
• Pancrazzi, A., Guglielmelli, P., Ponziani, V., Bergamaschi, G., Bosi, A., Barosi, G., Vannucchi, A. M. (2008). A Sensitive Detection Method for MPLW515L or MPLW515K Mutation in Chronic Myeloproliferative Disorders with Locked Nucleic Acid-Modified Probes and Real-Time Polymerase Chain Reaction. J. Mol. Diagn. 10: 435-441 [Abstract] [Full Text]  
• Maciejewski, J. P., Mufti, G. J. (2008). Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 112: 965-974 [Abstract] [Full Text]  
• Plo, I., Nakatake, M., Malivert, L., de Villartay, J.-P., Giraudier, S., Villeval, J.-L., Wiesmuller, L., Vainchenker, W. (2008). JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 112: 1402-1412 [Abstract] [Full Text]  
• Mirza, I, Sekora, D, Frantz, C (2008). Testing for JAK2V617F mutation across specimen types yields concordant results. J. Clin. Pathol. 61: 975-975 [Full Text]  
• Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Pancrazzi, A., Guerini, V., Barosi, G., Ruggeri, M., Specchia, G., Lo-Coco, F., Delaini, F., Villani, L., Finotto, S., Ammatuna, E., Alterini, R., Carrai, V., Capaccioli, G., Lollo, S. D., Liso, V., Rambaldi, A., Bosi, A., Barbui, T. (2008). Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 112: 844-847 [Abstract] [Full Text]  
• Spivak, J. L., Silver, R. T. (2008). The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 112: 231-239 [Full Text]  
• Gakovic, M., Ragimbeau, J., Francois, V., Constantinescu, S. N., Pellegrini, S. (2008). The Stat3-activating Tyk2 V678F Mutant Does Not Up-regulate Signaling through the Type I Interferon Receptor but Confers Ligand Hypersensitivity to a Homodimeric Receptor. J. Biol. Chem. 283: 18522-18529 [Abstract] [Full Text]  
• Cazzola, M. (2008). Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis. haematol 93: 967-972 [Full Text]  
• Vannucchi, A. M., Guglielmelli, P. (2008). Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations. haematol 93: 972-976 [Full Text]  
• Wang, L., Fidler, C., Nadig, N., Giagounidis, A., Della Porta, M. G., Malcovati, L., Killick, S., Gattermann, N., Aul, C., Boultwood, J., Wainscoat, J. S. (2008). Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. haematol 93: 994-1000 [Abstract] [Full Text]  
• Beer, P. A., Campbell, P. J., Scott, L. M., Bench, A. J., Erber, W. N., Bareford, D., Wilkins, B. S., Reilly, J. T., Hasselbalch, H. C., Bowman, R., Wheatley, K., Buck, G., Harrison, C. N., Green, A. R. (2008). MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112: 141-149 [Abstract] [Full Text]  
• Jeong, E. G., Kim, M. S., Nam, H. K., Min, C. K., Lee, S., Chung, Y. J., Yoo, N. J., Lee, S. H. (2008). Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers. Clin. Cancer Res. 14: 3716-3721 [Abstract] [Full Text]  
• Hexner, E. O., Serdikoff, C., Jan, M., Swider, C. R., Robinson, C., Yang, S., Angeles, T., Emerson, S. G., Carroll, M., Ruggeri, B., Dobrzanski, P. (2008). Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663-5671 [Abstract] [Full Text]  
• Velculescu, V. E. (2008). Defining the blueprint of the cancer genome. Carcinogenesis 29: 1087-1091 [Abstract] [Full Text]  
• Kiladjian, J.-J., Cervantes, F., Leebeek, F. W. G., Marzac, C., Cassinat, B., Chevret, S., Cazals-Hatem, D., Plessier, A., Garcia-Pagan, J.-C., Murad, S. D., Raffa, S., Janssen, H. L. A., Gardin, C., Cereja, S., Tonetti, C., Giraudier, S., Condat, B., Casadevall, N., Fenaux, P., Valla, D. C. (2008). The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111: 4922-4929 [Abstract] [Full Text]  
• Xing, S., Wanting, T. H., Zhao, W., Ma, J., Wang, S., Xu, X., Li, Q., Fu, X., Xu, M., Zhao, Z. J. (2008). Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 111: 5109-5117 [Abstract] [Full Text]  
• Dusa, A., Staerk, J., Elliott, J., Pecquet, C., Poirel, H. A., Johnston, J. A., Constantinescu, S. N. (2008). Substitution of Pseudokinase Domain Residue Val-617 by Large Non-polar Amino Acids Causes Activation of JAK2. J. Biol. Chem. 283: 12941-12948 [Abstract] [Full Text]  
• Xiao, Z., Zhang, Y., Li, L., Nie, L., Yang, L., Xu, S. (2008). The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders. haematol 93: 787-788 [Full Text]  
• Lipka, D. B., Hoffmann, L. S., Heidel, F., Markova, B., Blum, M.-C., Breitenbuecher, F., Kasper, S., Kindler, T., Levine, R. L., Huber, C., Fischer, T. (2008). LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Molecular Cancer Therapeutics 7: 1176-1184 [Abstract] [Full Text]  
• Xiang, Z., Zhao, Y., Mitaksov, V., Fremont, D. H., Kasai, Y., Molitoris, A., Ries, R. E., Miner, T. L., McLellan, M. D., DiPersio, J. F., Link, D. C., Payton, J. E., Graubert, T. A., Watson, M., Shannon, W., Heath, S. E., Nagarajan, R., Mardis, E. R., Wilson, R. K., Ley, T. J., Tomasson, M. H. (2008). Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 111: 4809-4812 [Abstract] [Full Text]  
• Grebien, F., Kerenyi, M. A., Kovacic, B., Kolbe, T., Becker, V., Dolznig, H., Pfeffer, K., Klingmuller, U., Muller, M., Beug, H., Mullner, E. W., Moriggl, R. (2008). Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood 111: 4511-4522 [Abstract] [Full Text]  
• Loriaux, M. M., Levine, R. L., Tyner, J. W., Frohling, S., Scholl, C., Stoffregen, E. P., Wernig, G., Erickson, H., Eide, C. A., Berger, R., Bernard, O. A., Griffin, J. D., Stone, R. M., Lee, B., Meyerson, M., Heinrich, M. C., Deininger, M. W., Gilliland, D. G., Druker, B. J. (2008). High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 111: 4788-4796 [Abstract] [Full Text]  
• Tomasson, M. H., Xiang, Z., Walgren, R., Zhao, Y., Kasai, Y., Miner, T., Ries, R. E., Lubman, O., Fremont, D. H., McLellan, M. D., Payton, J. E., Westervelt, P., DiPersio, J. F., Link, D. C., Walter, M. J., Graubert, T. A., Watson, M., Baty, J., Heath, S., Shannon, W. D., Nagarajan, R., Bloomfield, C. D., Mardis, E. R., Wilson, R. K., Ley, T. J. (2008). Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 111: 4797-4808 [Abstract] [Full Text]  
• Tiedt, R., Hao-Shen, H., Sobas, M. A., Looser, R., Dirnhofer, S., Schwaller, J., Skoda, R. C. (2008). Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111: 3931-3940 [Abstract] [Full Text]  
• Mannucci, P. M., Peyvandi, F. (2008). Thrombophilia Screening: Little Role for the JAK2V617F Mutation. Mayo Clin Proc. 83: 398-399 [Full Text]  
• Li, S., Kralovics, R., De Libero, G., Theocharides, A., Gisslinger, H., Skoda, R. C. (2008). Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 111: 3863-3866 [Abstract] [Full Text]  
• Wernig, G., Gonneville, J. R., Crowley, B. J., Rodrigues, M. S., Reddy, M. M., Hudon, H. E., Walz, C., Reiter, A., Podar, K., Royer, Y., Constantinescu, S. N., Tomasson, M. H., Griffin, J. D., Gilliland, D. G., Sattler, M. (2008). The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 111: 3751-3759 [Abstract] [Full Text]  
• Landolfi, R., Di Gennaro, L. (2008). Prevention of thrombosis in polycythemia vera and essential thrombocythemia. haematol 93: 331-335 [Full Text]  
• Lu, X., Huang, L. J.-S., Lodish, H. F. (2008). Dimerization by a Cytokine Receptor Is Necessary for Constitutive Activation of JAK2V617F. J. Biol. Chem. 283: 5258-5266 [Abstract] [Full Text]  
• Hama, A., Yagasaki, H., Takahashi, Y., Matsumoto, K., Kiyoi, H., Kojima, S. (2008). Response: Mutations of JAK2, JAK3 and GATA1 in acute megakaryoblastic leukemia of Down syndrome. Blood 111: 2493-2494 [Full Text]  
• Teofili, L., Foa, R., Giona, F., Larocca, L. M. (2008). Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?. haematol 93: 169-172 [Full Text]  
• Verstovsek, S., Manshouri, T., Quintas-Cardama, A., Harris, D., Cortes, J., Giles, F. J., Kantarjian, H., Priebe, W., Estrov, Z. (2008). WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation. Clin. Cancer Res. 14: 788-796 [Abstract] [Full Text]  
• Gondek, L. P., Tiu, R., O'Keefe, C. L., Sekeres, M. A., Theil, K. S., Maciejewski, J. P. (2008). Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111: 1534-1542 [Abstract] [Full Text]  
• Pietra, D., Li, S., Brisci, A., Passamonti, F., Rumi, E., Theocharides, A., Ferrari, M., Gisslinger, H., Kralovics, R., Cremonesi, L., Skoda, R., Cazzola, M. (2008). Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 111: 1686-1689 [Abstract] [Full Text]  
• Kawamata, N., Ogawa, S., Zimmermann, M., Kato, M., Sanada, M., Hemminki, K., Yamatomo, G., Nannya, Y., Koehler, R., Flohr, T., Miller, C. W., Harbott, J., Ludwig, W.-D., Stanulla, M., Schrappe, M., Bartram, C. R., Koeffler, H. P. (2008). Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 111: 776-784 [Abstract] [Full Text]  
• Kirsammer, G., Jilani, S., Liu, H., Davis, E., Gurbuxani, S., Le Beau, M. M., Crispino, J. D. (2008). Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood 111: 767-775 [Abstract] [Full Text]  
• Ruggeri, M., Rodeghiero, F., Tosetto, A., Castaman, G., Scognamiglio, F., Finazzi, G., Delaini, F., Mico, C., Vannucchi, A. M., Antonioli, E., De Stefano, V., Za, T., Gugliotta, L., Tieghi, A., Mazzucconi, M. G., Santoro, C., Barbui, T., for the Gruppo Italiano Malattie Ematologiche dell, (2008). Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood 111: 666-671 [Abstract] [Full Text]  
• Malcovati, L., Cazzola, M. (2008). Myelodysplastic/myeloproliferative disorders. haematol 93: 4-6 [Full Text]  
• Schmitt-Graeff, A. H., Teo, S.-S., Olschewski, M., Schaub, F., Haxelmans, S., Kirn, A., Reinecke, P., Germing, U., Skoda, R. C. (2008). JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. haematol 93: 34-40 [Abstract] [Full Text]  
• Antonioli, E., Guglielmelli, P., Poli, G., Bogani, C., Pancrazzi, A., Longo, G., Ponziani, V., Tozzi, L., Pieri, L., Santini, V., Bosi, A., Vannucchi, A. M., for the Myeloproliferative Disorders Research Cons, (2008). Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. haematol 93: 41-48 [Abstract] [Full Text]  
• Sotlar, K., Bache, A., Stellmacher, F., Bultmann, B., Valent, P., Horny, H.-P. (2008). Systemic Mastocytosis Associated with Chronic Idiopathic Myelofibrosis: A Distinct Subtype of Systemic Mastocytosis-Associated Clonal Hematological Nonmast Cell Lineage Disorder Carrying the Activating Point Mutations KITD816V and JAK2V617F. J. Mol. Diagn. 10: 58-66 [Abstract] [Full Text]